Somak Chatterjee

Somak Chatterjee

Auto-generated profile, based on publicly available information

Somak Chatterjee

Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KCKatie Chon
Katie Chon
ELErin Larkins
Erin Larkins
SCSomak Chatterjee
Somak Chatterjee
PMPallavi S. Mishra-Kalyani
Pallavi S. Mishra-Kalyani
SAStephanie Aungst
Stephanie Aungst
HSHarpreet Singh
Harpreet Singh
The FDA granted accelerated approval for amivantamab-vmjw (hereafter referred to as amivantamab), a bispecific antibody directed against EGFR and mesenchymal–epithelial transition receptor, on May 21, 2021, for the treatment of adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. Approval was based on results of an ongoing, multicenter, nonrandomized, open-label, multicohort clinical trial (CHRYSALIS, NCT 02609776), demonstrating a substantial overall response rate (ORR) and durable responses, with an ORR of 40% [95% confidence interval (CI): 29–51] and a median response duration of 11.1 months (95% CI: 6.9–not evaluable). Guardant360 CDx was contemporaneously approved as a companion diagnostic for this indication to identify EGFR exon 20 insertion mutations in plasma specimens. The most notable safety finding was the high incidence (66%) of infusion-related reactions, which is addressed in both the Dosage and Administration and Warnings and Precautions sections of the product label. Other common adverse reactions (occurring in ≥20% of patients) were rash, paronychia, musculoskeletal pain, dyspnea, nausea and vomiting, fatigue, edema, stomatitis, cough, and constipation. The approval of amivantamab was the first approval of a targeted therapy for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations.

7 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TPTimil H. Patel
Timil H. Patel
LMLeigh Marcus
Leigh Marcus
MHM. Naomi Horiba
M. Naomi Horiba
MDMartha Donoghue
Martha Donoghue
SCSomak Chatterjee
Somak Chatterjee
LFLola A. Fashoyin-Aje
Lola A. Fashoyin-Aje
On April 17, 2020, the FDA granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. Approval was based on FIGHT-202 (NCT02924376), a multicenter open-label single-arm trial. Efficacy was based on 107 patients with locally advanced unresectable or metastatic cholangiocarcinoma whose disease had progressed on or after at least one prior therapy and had an FGFR2 gene fusion or rearrangement. Patients received pemigatinib, 13.5 mg orally, once daily for 14 consecutive days, followed by 7 days off therapy. Safety was based on a total of 466 patients, 146 of whom had cholangiocarcinoma and received the recommended dose. Efficacy endpoints were overall response rate (ORR) and duration of response (DOR) determined by an independent review committee using RECIST 1.1. ORR was 36% (95% confidence interval: 27–45). Median DOR was 9.1 months. The most common adverse reactions were hyperphosphatemia, alopecia, diarrhea, nail toxicity, fatigue, dysgeusia, nausea, constipation, stomatitis, dry eye, dry mouth, decreased appetite, vomiting, arthralgia, abdominal pain, hypophosphatemia, back pain, and dry skin. Ocular toxicity and hyperphosphatemia are important risks of pemigatinib. The recommended dosage is 13.5 mg orally once daily for 14 consecutive days followed by 7 days off therapy in 21-day cycles. FDA also approved the FoundationOne CDX (Foundation Medicine, Inc.) as a companion diagnostic for patient selection.

14 January 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
SSSonia Singh
Sonia Singh
DBDiana Bradford
Diana Bradford
SCSomak Chatterjee
Somak Chatterjee
XLXiaoxue Li
Xiaoxue Li
SAStephanie L. Aungst
Stephanie L. Aungst
NDNicole Drezner
Nicole Drezner
On April 23, 2024, the FDA granted accelerated approval to tovorafenib, a type II RAF kinase inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement or BRAF V600 mutation. Efficacy was evaluated in FIREFLY-1 (NCT04775485), a single-arm, open-label, multicenter trial that enrolled patients 6 months to 25 years of age with relapsed or refractory pLGG with an activating BRAF alteration who had received prior systemic therapy. The major efficacy outcome measure was the radiologic overall response rate, defined as the proportion of patients with complete response, partial response, or minor response as determined by blinded independent central review using Response Assessment in Pediatric Neuro-Oncology criteria. A key secondary endpoint was duration of response. In an efficacy population of 76 patients, the overall response rate was 51% (95% confidence interval, 40–63), and the median duration of response was 13.8 months (95% confidence interval, 11.3–not estimable). The required postmarketing clinical trial (FIREFLY-2) was well underway at the time of accelerated approval. This represents the first FDA approval of a systemic therapy for the treatment of patients with pLGG with BRAF fusions or rearrangements.

13 May 2025
Verified
Other
Open access
SSSonia Singh
Sonia Singh
DBDiana Bradford
Diana Bradford
SCSomak Chatterjee
Somak Chatterjee
XLXiaoxue Li
Xiaoxue Li
SAStephanie L. Aungst
Stephanie L. Aungst
NDNicole Drezner
Nicole Drezner
Table S1 shows select laboratory abnormalities of at least 20% in frequency that worsened from baseline in patients with pediatric low-grade glioma who received tovorafenib in FIREFLY-1.

17 June 2026
Verified
Other
Open access
SSSonia Singh
Sonia Singh
DBDiana Bradford
Diana Bradford
SCSomak Chatterjee
Somak Chatterjee
XLXiaoxue Li
Xiaoxue Li
SAStephanie L. Aungst
Stephanie L. Aungst
NDNicole Drezner
Nicole Drezner
Table S1 shows select laboratory abnormalities of at least 20% in frequency that worsened from baseline in patients with pediatric low-grade glioma who received tovorafenib in FIREFLY-1.

22 October 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
RERachel Ershler
Rachel Ershler
XZXUEPING ZHOU
XUEPING ZHOU
KPKeng Hee Peh
Keng Hee Peh
HWHui Wei
Hui Wei
SCSomak Chatterjee
Somak Chatterjee
YKYvette L. Kasamon
Yvette L. Kasamon
In November 2025, the U.S. FDA granted traditional approval to epcoritamab-bysp in combination with lenalidomide and rituximab (R2) for adults with relapsed or refractory (R/R) follicular lymphoma (FL). Approval was based on EPCORE FL-1, a randomized, open-label trial evaluating fixed durations of epcoritamab in combination with R2 compared with R2 alone in patients with R/R FL. Efficacy was based on the dual primary endpoints of progression-free survival (PFS) and overall response rate (ORR), as assessed by an independent review committee (IRC). By intention-to-treat analysis (N = 488), PFS was statistically significantly longer in the epcoritamab plus R2 arm, with a hazard ratio of 0.21 [95% confidence interval (CI), 0.13–0.33] and P < 0.0001 on the first interim analysis. The median PFS was not reached [95% CI, 22–not reached (NR)] in the epcoritamab plus R2 arm and was 11.2 months (95% CI, 10.5–NR) in the R2 arm. The ORR per IRC was significantly higher in the epcoritamab plus R2 arm, based on a prespecified analysis of the first 232 patients assessed (96% vs. 81% with R2; P < 0.0001). This article summarizes key aspects of the regulatory review, including endpoint selection, randomized dose optimization, and a potential single-trial approach to support both accelerated and subsequent traditional approval.